

Drug Name: Nutropin NuSpin® (somatropin)

Last Revision Date: 06-2016

Date: 09-2017

Drug Name:	Nutropin NuSpin® (somatropin)
Required Medical Information:	<p><i>Patient's diagnosis is one of the following:</i></p> <ul style="list-style-type: none"> • Growth Hormone Deficiency (pediatrics): <ul style="list-style-type: none"> ○ Patient is being treated under the care of a pediatric endocrinologist; <i>and</i> ○ Patient has abnormally low values (< 10 ng/mL) of serum GH on two provocative tests; <i>and</i> ○ Patient height is greater than 2 standard deviations below the mean height for normal children of the same age; <i>and</i> ○ There is no evidence of epiphyseal closure after careful review; <i>and</i> ○ Patient has been evaluated for alternative diagnoses that suppress growth hormone secretion (e.g. hypothyroidism, chronic non-endocrine disease, etc.); <i>and</i> ○ With growth hormone therapy, patient demonstrates a continued growth rate of greater than 4 cm per year. • Small for gestational age (pediatrics): <ul style="list-style-type: none"> ○ Patient is being treated under the care of a pediatric endocrinologist; <i>and</i> ○ Patient has a birth weight and/or length that is at least 2 standard deviations below the mean for gestational age whose height remains less than or equal to 2 standards deviations below the mean by two years of age; <i>and</i> ○ Total treatment duration will not exceed 2 years. • Prader-Willi Syndrome (PWS) or Turner's Syndrome (pediatrics): <ul style="list-style-type: none"> ○ Patient is being treated under the care of a pediatric endocrinologist; <i>and</i> ○ Chromosomal information is consistent with the disease. • Idiopathic Short Stature (IDSS) (pediatrics): <ul style="list-style-type: none"> ○ Patient is being treated under the care of a pediatric endocrinologist; <i>and</i> ○ Patient has been evaluated for all other diagnoses that may cause short stature and demonstrates a predicted final height to be less than 3 standard deviations (which is

	<p>associated with growth rates that are unlikely to lead to adult height within the normal genetic potential); <i>and</i></p> <ul style="list-style-type: none"> ○ Patient's current bone age is 10 to 14. <ul style="list-style-type: none"> ● Growth Hormone Deficiency (adults): <ul style="list-style-type: none"> ○ Patient is under the care of an endocrinologist; <i>and</i> ○ Patient has documented abnormally low values (less than 10 ng/mL) of serum GH on two provocative tests; <i>and</i> ○ Patient is being treated for somatopin deficiency as a result of a pituitary disease, hypothalamic disease, surgery, trauma, radiation therapy, <u>OR</u> adult with child-onset growth hormone deficiency continues to require therapy for normal homeostasis. ● AIDS wasting or cachexia: <ul style="list-style-type: none"> ○ Patient has failed a trial of megestrol acetate (Megace®) at an adequate dose and for an appropriate duration due to intolerance and/or inadequate response; <i>and</i> ○ Patient is adherent to concomitant antiviral therapy. ● Growth failure associated with chronic renal insufficiency: <ul style="list-style-type: none"> ○ Patient has chronic kidney disease (CKD stage 4 or 5); <i>and</i> ○ Patient is in adequate metabolic control (PTH no less than 4 times normal, Ca 8.5-10.5 mg/dL, Phos 4.0-6.0 mg/dL) <u>AND</u> can maintain caloric intake needed to support growth; <i>and</i> ○ Growth hormone will significantly improve quality of life for patient who is in end stage renal disease and is awaiting renal transplant; <i>and</i> ○ Pediatric patient who has, prior to growth hormone treatment, demonstrated a growth rate of no less than 3 cm per year. ● Growth failure associated with chronic renal insufficiency in pediatric patients post-renal transplant: <ul style="list-style-type: none"> ○ Pediatric patient with recent renal transplant is maintained on stable immunosuppression; <i>and</i> ○ Patient has a post-transplant rate of less than 3 cm per year; <i>and</i> ○ There is no evidence of epiphyseal closure after careful review at 6-month intervals.
<p>Coverage Duration:</p>	<ul style="list-style-type: none"> ● Initial: 6 months ● Renewals: 6 months